A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Celldex Therapeutics logo

Celldex Therapeutics

Status and phase

Active, not recruiting
Phase 2

Conditions

Chronic Spontaneous Urticaria

Treatments

Biological: barzolvolimab
Drug: Matching Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05368285
CDX0159-06
2021-006413-11 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

Full description

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Spontaneous Urticaria. There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab. Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase.

Enrollment

208 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key inclusion criteria:

  1. Males and females, >/= 18 years of age.

  2. Diagnosis of chronic spontaneous urticaria (CSU) >/= 6 months.

  3. Diagnosis of CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:

    1. The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of H1-antihistamines.
    2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
    3. UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to treatment.
  4. Normal blood counts and liver function tests

  5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.

  6. Willing and able to complete a daily symptom electronic diary and comply with study visits.

Key exclusion criteria:

  1. Women who are pregnant or nursing.
  2. Clearly defined cause for chronic urticaria.
  3. Active, pruritic skin condition in addition to CSU.
  4. Medical condition that would cause additional risk or interfere with study procedures.
  5. Known active HIV, hepatitis B or hepatitis C infection.
  6. Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.
  7. History of anaphylaxis
  8. Prior treatment with barzolvolimab

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

208 participants in 6 patient groups

barzolvolimab 75 mg then 150 mg
Experimental group
Description:
barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks
Treatment:
Biological: barzolvolimab
barzolvolimab 75 mg then 300 mg
Experimental group
Description:
barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks
Treatment:
Biological: barzolvolimab
barzolvolimab 150 mg
Experimental group
Description:
barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks
Treatment:
Biological: barzolvolimab
barzolvolimab 300 mg
Experimental group
Description:
barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks
Treatment:
Biological: barzolvolimab
Placebo then barzolvolimab 150 mg
Experimental group
Description:
Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks
Treatment:
Drug: Matching Placebo
Biological: barzolvolimab
Placebo then barzolvolimab 300 mg
Experimental group
Description:
Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks
Treatment:
Drug: Matching Placebo
Biological: barzolvolimab

Trial contacts and locations

56

Loading...

Central trial contact

Celldex Therapeutics

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems